key: cord-0293124-udqjcaxs
authors: Weiss, Christopher M.; Liu, Hongwei; Ball, Erin E.; Lam, Samuel; Hode, Tomas; Keel, M. Kevin; Levenson, Richard M.; Coffey, Lark L.
title: N-dihydrogalactochitosan reduces mortality in a lethal mouse model of SARS-CoV-2
date: 2021-08-13
journal: bioRxiv
DOI: 10.1101/2021.08.10.455872
sha: ca5407b767b7a534f19c871b4075683ce2232943
doc_id: 293124
cord_uid: udqjcaxs

The rapid emergence and global dissemination of SARS-CoV-2 that causes COVID-19 continues to cause an unprecedented global health burden resulting in more than 4 million deaths in the 20 months since the virus was discovered. While multiple vaccine countermeasures have been approved for emergency use, additional treatments are still needed due to sluggish vaccine rollout and vaccine hesitancy. Immunoadjuvant compounds delivered intranasally can guide non-specific innate immune responses during the critical early stages of viral replication, reducing morbidity and mortality. N-dihydrogalactochitosan (GC) is a novel mucoadhesive immunostimulatory polymer of β-0-4-linked N-acetylglucosamine that is solubilized by the conjugation of galactose glycans. We tested GC as a potential countermeasure for COVID-19. GC administered intranasally before and after SARS-CoV-2 exposure diminished morbidity and mortality in humanized ACE2 receptor expressing mice by up to 75% and reduced infectious virus levels in the upper airway and lungs. Our findings demonstrate a new application for soluble immunoadjuvants like GC for preventing severe disease associated with SARS-CoV-2. Single Sentence Summary The immunoadjuvant N-dihydrogalactochitosan diminishes SARS-CoV-2 disease in humanized ACE2 mice representing a new countermeasure against COVID-19.

deaths in the 20 months since the virus was discovered. While multiple vaccine 27 countermeasures have been approved for emergency use, additional treatments are still 28 needed due to sluggish vaccine rollout and vaccine hesitancy. Immunoadjuvant compounds 29 delivered intranasally can guide non-specific innate immune responses during the critical early 30 stages of viral replication, reducing morbidity and mortality. N-dihydrogalactochitosan (GC) is a 31 novel mucoadhesive immunostimulatory polymer of β -0-4-linked N-acetylglucosamine that is 32 solubilized by the conjugation of galactose glycans. We tested GC as a potential 33 countermeasure for COVID-19. GC administered intranasally before and after SARS-CoV-2 34 exposure diminished morbidity and mortality in humanized ACE2 receptor expressing mice by 35 up to 75% and reduced infectious virus levels in the upper airway and lungs. Our findings 36 demonstrate a new application for soluble immunoadjuvants like GC for preventing severe 37 disease associated with SARS-CoV-2. include fever, non-productive cough, and mild to moderate dyspnea, with severe cases 45 developing pneumonia and acute respiratory distress syndrome (1) (2) (3) . SARS-CoV-2 morbidity 46 and mortality increase with age and systemic proinflammatory and cardiovascular co-morbidities 47 (1, 2, 4) . Recovered patients may also exhibit long-duration symptoms including disruption to 48 sensations of taste and smell, and cognitive impairment (colloquially referred to as "brain fog") 49 resulting from neurological involvement (5, 6). 50 Like SARS-CoV, SARS-CoV-2 uses the angiotensin converting enzyme 2 (ACE2) for 51 cell entry (7, 8) . Small animals including mice, hamsters, and ferrets, have been fundamental in 52 defining SARS-CoV-2 pathogenesis and developing medical countermeasures (9, 10). 53 Transgenic mice expressing the human ACE2 (hACE2) gene from the human cytokeratin 18 54 (K18) promoter have served as an especially useful model of severe disease due to well 55 characterized genetics and ease of use (11) (12) (13) . Intranasal inoculation of K18-hACE2 mice 56 (hereafter termed hACE2) with SARS-CoV-2 results in a high viral burden in the lungs, which 57 diminishes past day 7, and elevated viral loads detectible in the brain at day 7 (12) . 58 SARS-CoV-2, which can be transmitted in small-droplet aerosols from person to person, 59 can take up to 14 days to produce symptoms (14) . Public health countermeasures have evolved 60 as additional treatments and information regarding transmission risks for COVID-19 have 61 become available. In addition to face coverings and physical distancing, multiple vaccine 62 candidates have now received emergency use authorization by the United States Food and 63 Drug Administration (FDA) (15). While 'herd immunity' through vaccination remains the target, it 64 is estimated that 70-90% of the global population must be immune in order to interrupt 65 4 transmission (16). This target becomes even more challenging with high levels of vaccine 66 skepticism, slow production, inequitable distribution, and the rise of variants of concern capable 67 of more efficient transmission or vaccine escape. Pre-and post-exposure countermeasures can 68 help fill the vaccine gap by reducing COVID-19 morbidity and mortality in unprotected 69 communities and thus reduce the global burden of the pandemic. The nucleoside analog 70 remdesivir (17) is the only current FDA-approved therapeutic and was authorized based on its 71 ability to shorten recovery time in COVID-19 patients (18) against SARS-CoV-2. Furthermore, non-specific immunoadjuvants such as GC could offer a 102 benefit over more narrowly targeted antivirals by providing protection against a range of 103 pathogens, potentially including future agents not yet affecting public health. 104 In the present study, we explored the use of GC for prophylaxis against SARS-CoV-2 105 infection applied pre-and post-exposure to lethal dosages of the virus in transgenic hACE2 106 mice. To simulate the use of solubilized GC as a nasal spray, we applied the compound 107 intranasally twice before exposure and once following exposure of mice to a human isolate of 108 SARS-CoV-2. Our data demonstrate a strong protective effect from GC in preventing mortality To determine the antiviral efficacy of N-dihydrogalactochitosan (GC) against SARS- 117 CoV-2, 6-week-old hACE2 [B6.Cg-Tg(K18-ACE2)2Prlmn/J] mice were treated intranasally (i.n.) 118 with 0.75% of GC in neutral buffered saline 3 and 1 days prior to virus exposure and 1 day post 119 exposure ( Fig. 1a) . Inhaled GC was well tolerated in mice, and no adverse events were noted 120 during or after treatment. Mice were challenged i.n. 1 day prior to the final GC treatment with 10 3 121 or 10 4 plaque forming units (PFU) of SARS-CoV-2, a route and dose intended to produce high 122 lethality in this model. Inocula were back-titrated to verify the administered dose. Tracheal 123 swabs were collected for the first 3 days post challenge and animals were monitored daily until 124 day 14 for weight loss and health status. 125 Weight remained stable for the first 3 days in all groups and infected controls rapidly 126 declined starting at day 4 in 10 4 PFU and day 5 in 10 3 PFU groups (Fig. 1b) . Half of mice 127 experienced no weight loss throughout the duration of the study (Supplementary Fig. 1) ; 128 conversely, their growth outpaced mock-infected counterparts treated with saline alone 129 (p<0.0001). This effect was not limited to one biological sex and did not correlate with mouse Fig. 1c) . At the lower challenge dose of 10 3 PFU, GC had an efficacy of 37.5% 140 protection from mortality (p=0.05) (Fig. 1d) . At the higher challenge dose of 10 4 PFU, GC 141 7 reduced SARS-CoV-2 mortality by 75% (p<0.0001). Together, these results demonstrate the 142 potent efficacy of GC in preventing fatal SARS-CoV-2 disease in transgenic mice. 143 144 N-dihydrogalactochitosan reduces SARS-CoV-2 viral levels in the upper respiratory tract. 145 We next sought to determine whether GC reduced viral levels in addition to protecting mice from 146 mortality. Infectious SARS-CoV-2 levels were assessed longitudinally in mice by swabbing 147 throats from day 1 to 3 post-challenge (Fig. 2a) . SARS-CoV-2 was detectible in the trachea of 168 Comparatively high viral titers were observed in the brain at the time of death, consistent 169 with previous descriptions in this model (12) . Virus was detectible in the brain in all but 2 170 infected animals at the time of death, indicating neuroinvasion as a likely cause of morbidity. Table 1 ) and the total area of the lung that was affected was estimated using image analysis 190 software (Fig. 3e) . GC treatment significantly reduced the mean severity score for animals 191 dosed with 10 4 PFU SARS-CoV-2 from 4.6 to 2.5 (ANOVA, p < 0.0001). Mean scores for mice 192 9 treated with GC and 10 3 PFU of SARS-CoV-2 trended towards being lower than for mice who 193 did not receive GC but were not significantly different (p >0.05). The percent of lung affected in 194 mice that received the 10 4 SARS-CoV-2 dose was also significantly reduced from a mean of 195 33% to 13% (p<0.0001); differences at the 10 3 dose were not significant. Fig. 2b,c) . 204 Together, these data show that GC reduces SARS-CoV-2-induced disease in the lung of Within normal limits or rare, scattered lymphocytic infiltrates not observed in control animals but significance questionable (could be background lesion or variation of normal).

1 minimal Minimal mononuclear inflammation affecting less than 2% of the section. Inflammatory leukocyte infiltration is limited to a perivascular and/or peribronchiolar distribution with no evidence of alveolar or vascular injury.

Mild peribronchiolar/perivascular inflammation which may also expand alveoli/alveolar septa, composed primarily of macrophages and lymphocytes (+/-scattered neutrophils); increased alveolar macrophages; alveolar septal architecture largely intact; affects 2-10% of the section; and/or scattered alveolar hemorrhage/fibrin/edema; and/or scattered atypical/multinucleated syncytial cells.

Moderate bronchointerstitial and perivascular inflammation, increased alveolar macrophages, and/or alveolar hemorrhage/fibrin/edema (characterized as above); and/or alveolar damage (characterized by type I pneumocyte necrosis or loss with replacement by hyaline membranes, fibrin, edema, and/or necrotic debris); and/or reparative/regenerative changes (type II pneumocyte hyperplasia, atypical/multinucleated syncytial cells, or fibrosis); lesions affect 10-25% of the section. 4 severe As above but more widespread inflammation, hemorrhage/fibrin/ edema, and/or alveolar damage/loss of normal septal architecture; and or regenerative changes affecting greater than 25% of the section.

Add 1 point if: Greater than 25% of inflammatory cells are neutrophils; there is significant necrotizing vasculitis, endotheliitis or microthrombi; or if there is significant bronchiolitis, airway epithelial necrosis or hyperplasia. 

Clinical features of patients infected with 2019 569 novel coronavirus in

Clinical Characteristics of 138 Hospitalized Patients with

Novel Coronavirus-Infected Pneumonia in Wuhan, China

Epidemiological and clinical characteristics of 99 cases of 2019 576 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical course and risk factors for 580 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Persistent COVID-19-associated neurocognitive symptoms in non-585 hospitalized patients

Persistent neurologic 588 symptoms and cognitive dysfunction in non-hospitalized Covid-19 "long haulers

Genomic characterisation and epidemiology of 2019 novel coronavirus: 594 implications for virus origins and receptor binding

A pneumonia outbreak associated with a new coronavirus of probable bat 599 origin

The search for a COVID-19 animal model

Animal models for COVID-19

Lethal 615 Infection of K18-hACE2 Mice Infected with Severe Acute Respiratory Syndrome Coronavirus

SARS-CoV-2 infection of human ACE2-transgenic mice causes 620 severe lung inflammation and impaired function

COVID-19 treatments 623 and pathogenesis including anosmia in K18-hACE2 mice

14. Symptoms of COVID-19 | CDC

FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine | FDA

Coronavirus disease (COVID-19): Herd immunity, lockdowns and COVID-19

Veklury (remdesivir) EUA Letter of Approval

Remdesivir 638 for the Treatment of Covid-19 -Final Report

19. WHO recommends against the use of remdesivir in COVID-19 patients

20. Food and Drug Administration, FDA Combating COVID-19 With Therapeutics

The antiviral activity of chitosan (review)Appl

Chitosan-based 647 nanoparticles in mucosal vaccine deliveryArch

Chitin, chitosan, and glycated chitosan regulate immune responses: The novel adjuvants for 650 cancer vaccineClin

Immunomodulatory role of chitosan-based 652 nanoparticles and oligosaccharides in cyclophosphamide-treated mice

A lipid/DNA adjuvant-inactivated influenza virus vaccine protects rhesus 656 macaques from uncontrolled virus replication afer heterosubtypic influenza a virus challenge

Activation and evasion of type I interferon responses by 660 SARS-CoV-2

Evasion of Type I Interferon by SARS-CoV-2

Interplay between SARS-CoV-2 and the 665 type I interferon responsePLoS Pathog

Intranasal 667 Administration of Chitosan Against Influenza A (H7N9) Virus Infection in a Mouse Model

Intranasal immunization with live attenuated influenza vaccine plus 671 chitosan as an adjuvant protects mice against homologous and heterologous virus challenge

Immunomodulating Adjuvant on T-Cells and Antigen-Presenting Cells in Herpes Simplex Virus 675

Type 1 Infection

Laser immunotherapy: A novel treatment 677 modality for metastatic tumors

Glycated chitosan as a 680 new non-toxic immunological stimulant Glycated chitosan immunological stimulant

Receptor and Immunity: When the Ligand Can Make the Difference

N-dihydrogalactochitosan-supported tumor control by photothermal therapy and 687 photothermal therapy-generated vaccine

Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune 691 EfficacyCells

Neutrophil 693 infiltration and whole-cell vaccine elicited by N-dihydrogalactochitosan combined with NIR 694 phototherapy to enhance antitumor immune response and T cell immune memory

Local phototherapy 697 synergizes with immunoadjuvant for treatment of pancreatic cancer through induced 698 immunogenic tumor vaccine

N-700 dihydrogalactochitosan as a potent immune activator for dendritic cells

ScRNA-seq reveals tumor microenvironment remodeling 704 induced by local intervention-based immunotherapy, bioRxiv

SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections

Ugly" of Chitosans

Utilization of byproducts and 714 waste materials from meat, poultry and fish processing industries: A reviewJ

Advancement on modification of chitosan biopolymer and its potential applicationsInt

Evaluation of hydrophobic chitosan-based particulate formulations of porcine reproductive and 722 respiratory syndrome virus vaccine candidate T cell antigens

Induction of Th2 response through 724 TLR2-mediated MyD88-dependent pathway in human microfold cells stimulated with chitosan 725 nanoparticles loaded with Brucella abortus Mdh

CoV activates interleukin-6 expression through cellular transcription factor NF-κB

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Early IL-6 signalling promotes IL-27

dependent maturation of regulatory T cells in the lungs and resolution of viral immunopathology

Chitosan but not chitin activates the inflammasome by a mechanism dependent upon 739 phagocytosis

The Vaccine Adjuvant Chitosan Promotes Cellular Immunity via DNA 743

Sensor cGAS-STING-Dependent Induction of Type I Interferons

Polysaccharides as vaccine 745 adjuvantsVaccine

Effective nasal influenza vaccine delivery using chitosan

Carbohydrate immune adjuvants in subunit 752 vaccinesPharmaceutics

Innate Sensing of Chitin and Chitosan

X-ray 756 crystal structure of the human galectin-3 carbohydrate recognition domain at 2.1-Å resolution

Synthesis of 759 chitooligomer-based glycoconjugates and their binding to the rat natural killer cell activation 760 receptor NKR-P1

Antitumor immunologically 762 modified carbon nanotubes for photothermal therapy

Polyglutamic acid-trimethyl chitosan-based intranasal peptide nano-765 vaccine induces potent immune responses against group A streptococcus

Potential targets for next generation antimicrobial 768 glycoconjugate vaccinesFEMS